34 results about "Luteal phase" patented technology

The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.

A method for preventing or treating a catamenial migrainous disorder in a female subject comprises administering to a vulvovaginal surface of the subject a pharmaceutical composition that is bioadhesive thereto and comprises at least one estrogenic compound in an amount of about 50 μg to about 1000 μg estradiol equivalent per unit dose of the composition. A related method comprises administering to a vulvovaginal surface of the subject a pharmaceutical composition comprising at least one estrogenic compound, wherein upon administration of the composition to the vulvovaginal surface, a decline in serum estradiol concentration during a luteal phase of a menstrual cycle is moderated.

The present invention relates to a method of treating disorders including cognition impairment, generalized anxiety disorder, acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder, social anxiety disorder, major depressive disorder, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine addiction, alcohol addiction, amphetamine addiction, Lesch-Nyhan syndrome, neurodegenerative diseases, late luteal phase syndrome, narcolepsy, psychiatric symptoms anger, rejection sensitivity, movement disorders, extrapyramidal syndrome, Tic disorder, restless leg syndrome, tardive dyskinesia, sleep related eating disorder, night eating syndrome, stress urinary incontinence, migraine, neuropathic pain, diabetic neuropathy, fibromyalgia syndrome, chronic fatigue syndrome, sexual dysfunction, premature ejaculation, and male impotence. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a disclosed compound. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein.

The present invention relates to a method of treating disorders including cognition impairment, generalized anxiety disorder, acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder, social anxiety disorder, major depressive disorder, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine addiction, alcohol addiction, amphetamine addiction, Lesch-Nyhan syndrome, neurodegenerative diseases, late luteal phase syndrome, narcolepsy, psychiatric symptoms anger, rejection sensitivity, movement disorders, extrapyramidal syndrome, Tic disorder, restless leg syndrome, tardive dyskinesia, sleep related eating disorder, night eating syndrome, stress urinary incontinence, migraine, neuropathic pain, diabetic neuropathy, fibromyalgia syndrome, chronic fatigue syndrome, sexual dysfunction, premature ejaculation, and male impotence. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a disclosed compound. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein.

The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.

The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase type 4.

A traditional Chinese medicinal pill for treating gynopathy is prepared through the following steps: mixing raw medicines, grinding the obtained mixture to form powder, and adding 200-300 parts by weight of yellow rice wine, wherein the raw medicines comprise, by weight, 20-60 parts of Rhizoma Cyperi processed with wine, vinegar, ginger and salt, 10-50 parts of Chinese angelica root, 5-30 parts of Ligusticum wallichii, 10-50 parts of white peony root, 10-50 parts of unprocessed rehmannia root, 10-50 parts of Poria cocos, 10-50 parts of Fructus Aurantii, 5-30 parts of Magnolia officinalia Rehd et wils, 5-25 parts of Areca catechu, 10-50 parts of Radix Astragali preparata, 15-25 parts of corydalis tuber, 5-20 parts of pinellia tuber, 10-50 parts of dried orange peel, 10-55 parts of prepared rehmannia root, 10-50 parts of safflower, 10-50 parts of Rhizoma Atractylodis Macrocephalae and 10-35 parts of honey-fried licorice root. The traditional Chinese medicinal pill has the advantages of reasonable compatibility, simple preparation method and no toxic or side effects, can activating blood circulation to dissipate blood stasis, rectify qi, relieve pains, soften hardness, dissipate binds, regulate menstruation, relieve leucorrhea, remove inflammation and kill bacteria, and especially has very substantial curative effects on mastopathy, fibroid, ovarian cyst, abnormal menstruation, dysmenorrhoea, pelvic inflammation, cervical erosion, colpitis, pruritus vulvue, luteal phase defect, infertility and other gynaecologic diseases.

A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural levelS thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg, preferably 2 mg-6 mg. In multiple dosing-posology, LH-RH antagonist can be administered subcutaneously in an amount in the range of 0.1 to 0.5 mg of LH-RH antagonist/day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addition rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralizing the negative effects of HCG.

The invention relates to a medicine for treating anovulatory dysfunctional uterine bleeding. Common symptom of anovulatory dysfunctional uterine bleeding is irregular metrorrhagia and is represented by irregular menstrual periods, unequal menstrual periods, indefinite or increased menstrual blood volume, and even excessive bleeding. No stomachache or other discomforts are available in the full bleeding period, secondary anemia always occurs when the amount of bleeding is great or the time is long, and excessive bleeding leads to shock. No abnormalities are found in general check-up and gynecologic examination, so that organic lesions of reproductive organ and general lesions are excluded. Ovulation is stopped through endometrium sample pathological examination, progesterone test in luteal phase and examination of basal body temperature. Through long-term research and clinical verification, the inventor finally finds a traditional Chinese medicine oral preparation for treating anovulatory dysfunctional uterine bleeding with better curative effect. The use level of medical components are found by the inventer, and the medicine comprises the components in parts by weight as follows: 10 parts of angelica sinensis, 10 parts of ligusticum wallichii, 10 parts of myrrh, 10 parts of trogopterus dung, 3 parts of pseudo-ginseng, 12 parts of the root bark of the peony tree, 10 parts of the root of red-rooted salvia, 6 parts of donkey-hide gelatin, 15 parts of fried folium artemisiae argyi, 20 parts of cuttle bone, 20 parts of keel and 15 parts of oyster. The medicines are combined, so that the medicines have the synergistic effect, and have the functions of promoting blood circulation to remove blood stasis, nourishing the blood and hemoslasis and regulating menstruation and relieving pain, so that the medicine can effectively treat anovulatory dysfunctional uterine bleeding.

The invention provides a traditional Chinese medicine composition for shortening mare luteal phase, and the traditional Chinese medicine composition comprises the following raw materials: toosendan fruit, bupleurum, semen litchi, fennel, frankincense, notopterygium and radix angelicae pubescentis. The traditional Chinese medicine composition uses the therapeutic principle of warming spleen and stomach for dispelling cold and benefiting qi for lifting yang, and is reasonable in prescription, simple in preparation process and wide in scope of application. The traditional Chinese medicine composition is prepared from pure Chinese herbal medicines, and is wide in source, low in cost, high in cure rate, free of medicine residue, and free of toxic and side effects. In particularly, after super fine crushing, maximum destruction of plant cell walls can be realized by the traditional Chinese medicine composition, and the traditional Chinese medicine composition solves the deficiency that traditional medicine powder is high in crude fiber content, and effective components are not easy to dissolving out, and is easy for absorption of horses. The traditional Chinese medicine composition has the effects of relieving, easing pains, and regulating body functions, effectively shortens the mare luteal phase, can shorten the recovery period, compared with western medicine treatment, and is free of recurrence.

The invention discloses activating molecule essential oil for the female luteal phase and a making method thereof. The activating molecule essential oil is prepared from, by weight, 8-20 parts of grape seed oil, 6-15 parts of rose oil, 3-8 parts of sweet orange peel oil, 4-10 parts of bergamot fruit oil, 7-12 parts of tea oil, 8-16 parts of eucalyptus globulus leaf oil, 3-7 parts of mint oil, 2-8parts of lavender oil, 5-14 parts of tocopherol, 20-30 parts of octyldodecanol oleate, 20-30 parts of argania spinosa kernel oil, 5-10 parts of egg yolk oil, 5-10 parts of squalane and 25-40 parts ofdicaprylyl carbonate. The making method for the activating molecule essential oil for the female luteal phase includes the multiple technology steps of preparing base oil, preparing essential oil, mixing and the like; after using, it is avoided that as follicles perish, and endometrium is about to fall off, the face gets pimples, and is exuberant in grease secretion and coarse in pore, all kinds of physiological pain discomfort such as blocking, pains, sensitivity, breast distending pains, abdominal distention and constipation of the body occur, and phenomena that the spirit is tense, fractious, somber, agitated and the like occur; after the liver and the gall are dredged, an effect of soothing the liver and regulating qi can be achieved.

A healthcare product for women in the menstrual period is prepared from raw material in parts by weight as follows: 10-20 parts of edible mushrooms, 15-20 parts of nuts, 2-8 parts of soybeans, 5-15 parts of quinoa, 8-12 parts of prebiotics and 1-5 parts of an antioxidant. When taken by the women in the first week of a luteal phase, the healthcare product has the advantages that follicular development can be promoted, estrogen can be supplemented, ovulation can be promoted, the kidney can be strengthened and tonified, the liver can be soothed, vital energy can be regulated, gastrointestinal functions can be coordinated, and bowel movement of the intestinal tract can be promoted.

The present invention discloses a method for increasing the timed insemination efficiency of gilts. The method includes: selecting healthy gilts with suitable ages, intramuscularly injecting 1000 IU of PMSG per gilt, and starting to execute a timed insemination program after 15-20 d. PMSG pretreatment on the silts is preformed at the early stage of a conventional timed insemination program to provide a follicular development process for the gilts, so that the gilts are in an artificial known estrus before the conventional timed insemination program, that is, a follicular luteal phase begins from the 15th d, a follicular development period begins from the 20th d, and the initial follicular development states of the overall population are consistent and controllable. Shown by a result, the consistency of the initial follicular states may increase the pregnancy rate, the total number of births and the number of live births after timed insemination program processing, so that the overall efficiency of timed insemination of the gilts is increased, defects of an existing program are effectively overcome, an existing timed insemination program is optimized, the reproduction performance ofthe gilts is increased, and thus, the economic benefit of a pig farm is increased.

The present invention is a method of a non-continuous administration of a pharmaceutical to a female for a condition associated with the female's menstrual cycle, compromising in the administration of either 7α-Acetylthio-3-oxo-17α-pregn-4-ene-21,17-carbolactone, (+)-(S)-2-(6-methoxynaphthalen-2-yl) propanoic acid or RS)-2-(4-(2-methylpropyl) phenyl) propanoic acid. The active ingredients to be manufactured into a tablet or chewable formulation rich in cocoa flavonols such as dark chocolate no more than 65%. A method of inhibiting one or more symptom of premenstrual syndrome/late luteal phase dysphoric disorder compromising of administering to a female in need of treatment an effective amount of a compound. The first dose to be given at the onset of the premenstrual symptoms. This can be given two to four times a day up to seven days as directed. This is intended to be a short course of therapy to alleviate the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder.

The present invention relates to a composition which is for preventing and ameliorating or treating premenstrual syndrome symptoms, and includes: (a) a Chrysanthemum zawadskii extract; (b) a mixture of the Chrysanthemum zawadskii extract and a malt extract; or (c) a mixture of the Chrysanthemum zawadskii extract, the malt extract, and an aloe extract. Specifically, the present compositions effectively inhibit the secretion of prolactin from pituitary cells, which is a phenomenon that appears during premenstrual syndrome, thereby increasing the secretion of progesterone, which is reduced during the luteal phase of women, and can thus be advantageously used as a composition for preventing and ameliorating or treating women's premenstrual syndrome.

The invention discloses a traditional Chinese medicine for treating a gynecological disease according to the physiologic periodic change of a female. The traditional Chinese medicine is characterized by being composed of the following raw materials in parts by weight: 15-25 parts of Rosa laevigata root, 15-25 parts of evodia, 5-10 parts of draconis sanguis, 1-5 parts of frankincense, 10-15 parts of myrrh, 15-25 parts of yerbadetajo, 5-15 parts of cuttlebone, 10-15 parts of phellodendron bark, 20-30 parts of kuh-seng, 15-25 parts of nutgall, 10-15 parts of pulvis fellis suis, 15-25 parts of Kochia scoparia, 10-15 parts of evodia lepta, 15-20 parts of radix geutianae, 10-15 parts of catechu, 10-20 parts of purslane, 5-8 parts of groundsel, 5-15 parts of pseudo-ginseng powder, 14-22 parts of coptis root, 6-8 parts of borneol, 15-18 parts of borax, 10-20 parts of herba polygoni avicularis, 9-18 parts of Cortex Dictamni, 5-15 parts of Radix lsatidis, 5-12 parts of fructus cnidii, 3-9 parts of glabrous greenbrier rhizome, 13-22 parts of taraxacum and 5-15 parts of dried alum. The traditional Chinese medicine has the following advantages: a plaster or powder can be selected for external use according to different physiological phases of a female; and meanwhile, a menstrual phase conditioning soup, a follicular phase conditioning soup, a luteal phase conditioning soup and a late luteal phase conditioning soup are used together with the traditional Chinese medicine, thereby achieving a favorable effect for treating a gynecologic disease.